Passage BIO PASG 深 滬
等待開盤 12-25 09:30:00 美东时间
10.89
+0.875
+8.74%
華盛通- 最 高11.32
- 今 開9.95
- 成交量 7.01万股
- 最 低 9.7287
- 昨 收 10.015
- 總市值 3461.60万
- 52周最高 20.20
- 市盈率 靜 --
- 換手率 2.20%
- 52周最低 5.1239
- 委 比 -33.33%
- 總股本 317.87万
- 歷史最高 764.60
- 量 比 1.60
- 振 幅 15.89%
- 歷史最低 5.14
- 每 手 1
- 風險率 2.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
11-13 09:58
Chardan Capital Maintains Buy on Passage Bio, Raises Price Target to $21
Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and raises the price target from $6 to $21.
11-12 20:33
Passage Bio Q3 EPS $(2.44) Beats $(2.80) Estimate
Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(2.80) by 12.86 percent. This is a 60.33 percent increase over losses of $(6.15) per share from the
11-11 05:37
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Passage Bio, Inc. (NASDAQ: PASG) announced that CEO Will Chou, M.D., will participate in a fireside chat at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on November 12, 2025, at 9:30 a.m. ET in Boston. A live webcast and replay of the event will be available on Passage Bio’s website. Passage Bio focuses on developing genetic medicines for neurodegenerative diseases, with its lead candidate PBFT02 targeting conditions like...
11-05 12:00
Passage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference
Passage Bio CEO Will Chou will participate in a panel discussion at the Chardan 9th Annual Genetic Medicines Conference on October 21, 2025. The event will be webcast live on Passage Bio’s website, with a replay available for 90 days. Passage Bio focuses on developing one-time therapies for neurodegenerative diseases, with its lead candidate PBFT02 targeting conditions like frontotemporal dementia. For more information, visit passagebio.com.
10-14 11:00
Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
Passage Bio, a clinical-stage genetic medicines company focused on treating neurodegenerative diseases, announced it will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City. CEO Will Chou will present an overview of the company, and a video webcast of the presentation will be available starting September 5, 2025. Passage Bio's lead product candidate, PBFT02, targets conditions l...
08-28 11:00
美股机会日报丨“恐怖数据”符合预期，交易员下调美联储降息预期；巴菲特Q2新建仓股飙升，联合健康盘前涨超10%
“恐怖数据”符合预期，交易员下调美联储降息预期；巴菲特Q2新建仓股盘前飙升，联合健康涨超10%，纽柯钢铁涨近5%；美俄首脑即将举行会晤>>
08-15 20:49
美股大行评级 | 潜在涨幅仍有782.74%！Passage BIO遭Canaccord Genuity下调目标价至67美元，维持"买入"评级
今日重点评级关注：Northland Capital Markets：维持BrainsWay"跑赢大市"评级，目标价从15美元升至19美元；Lake Street：维持Hyperfine"买入"评级，目标价从1.5美元升至2美元
08-15 09:30
Passage Bio shares are trading lower. The company reported worse-than-expected Q2 EPS results.
Passage Bio shares are trading lower. The company reported worse-than-expected ...
08-12 21:20
Passage Bio Q2 EPS $(2.96) Misses $(0.21) Estimate
Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.96) per share which missed the analyst consensus estimate of $(0.21) by 1309.52 percent. This is a 41.85 percent increase over losses of $(5.09) per share from
08-12 19:08
